How looming patent cliffs are impacting pharma IP strategies
Major IP expiries on the horizon are not only shaping pharma dealmaking patterns, but are likely to lead to further patent thicket disputes.
Source: iam-media.com
Stay updated with breaking news from Alerts How. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Major IP expiries on the horizon are not only shaping pharma dealmaking patterns, but are likely to lead to further patent thicket disputes.
Saturday Opinion: The prospect of an international agreement on the proposed suspension of TRIPS now appears vanishingly small
US life sciences leadership is at stake, industry tells USPTO, but comments on eligibility study show deep divisions remain